Antituberculosis medication as a possible epigenetic factor of Leber's hereditary optic neuropathy
Article first published online: 22 FEB 2010
© 2010 The Authors. Journal compilation © 2010 Royal Australian and New Zealand College of Ophthalmologists
Clinical & Experimental Ophthalmology
Volume 38, Issue 4, pages 363–366, May/June 2010
How to Cite
Seo, J. H., Hwang, J.-M. and Park, S. S. (2010), Antituberculosis medication as a possible epigenetic factor of Leber's hereditary optic neuropathy. Clinical & Experimental Ophthalmology, 38: 363–366. doi: 10.1111/j.1442-9071.2010.02240.x
- Issue published online: 11 JUN 2010
- Article first published online: 22 FEB 2010
- Received 16 August 2009; accepted 4 December 2009.
- antituberculosis medication;
- epigenetic factor;
- Leber's hereditary optic neuropathy
Purpose: To investigate if antituberculosis medication including ethambutol could be a possible epigenetic factor in visual loss in Leber's hereditary optic neuropathy (LHON).
Methods: The authors reviewed the medical records of 46 patients registered at Bundang Seoul National University Hospital from 2002 to 2006, who developed the typical clinical neuro-ophthalmologic features of LHON and possessed a mtDNA mutation at nucleotide 11778, 14484, 3460 or 4171.
Results: Three of the 46 patients developed visual loss while taking antituberculosis medication. These three patients had the mtDNA 11778 mutation with a mean age of 32.7 years at the onset of visual loss, whereas the mean age of other 43 patients was 21.2 years. One of these three patients was female.
Conclusion: Antituberculosis medication may be an epigenetic factor of LHON in patients with a primary LHON mutation. This risk should be recognized by physicians and LHON carriers.